Key Points
- Frank Giustra bought 1,000,000 shares at $3.00 per share (≈$3,000,000), raising his direct stake to 1,178,205 shares — a reported 561.15% increase disclosed to the SEC.
- Other insiders also bought shares — CIO Mitchell Young Williams acquired about 51,511 shares and director Morgan Lee Lekstrom made multiple purchases (including 41,000 and 23,000-share transactions) — a pattern that signals management confidence.
- Despite insider buying and a roughly 7.4% uptick in the stock, external signals are mixed: Weiss Ratings initiated coverage with a "Sell (D-)" and recent public-offering closings reporting ~$35M–$40.25M could boost liquidity but may imply shareholder dilution.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Director Morgan Lee Lekstrom bought 5,500 shares of the firm's stock in a transaction on Tuesday, January 27th. The stock was acquired at an average cost of $3.12 per share, for a total transaction of $17,160.00. Following the completion of the purchase, the director directly owned 76,500 shares in the company, valued at approximately $238,680. This represents a 7.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Monday, January 26th, Morgan Lee Lekstrom purchased 23,000 shares of Biosig Technologies stock. The stock was bought at an average price of $3.30 per share, with a total value of $75,900.00.
- On Friday, January 23rd, Morgan Lee Lekstrom acquired 41,000 shares of Biosig Technologies stock. The shares were bought at an average price of $3.13 per share, for a total transaction of $128,330.00.
Biosig Technologies Stock Up 7.4%
NASDAQ STEX opened at $3.65 on Wednesday. Biosig Technologies, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $14.11.
Analysts Set New Price Targets
Separately, Weiss Ratings initiated coverage on shares of Biosig Technologies in a report on Friday. They issued a "sell (d-)" rating on the stock. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of "Sell".
Check Out Our Latest Stock Analysis on STEX
Key Biosig Technologies News
Here are the key news stories impacting Biosig Technologies this week:
- Positive Sentiment: Major shareholder Frank Giustra bought 1,000,000 shares at $3.00 (≈$3.0M), increasing his direct stake to 1,178,205 shares — a large, confidence-signaling purchase disclosed to the SEC. SEC Filing
- Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares at ~$3.03, raising his holdings to ~1,051,511 shares — another insider buy that supports management confidence. SEC Filing
- Positive Sentiment: Director Morgan Lee Lekstrom executed multiple purchases (including 41,000 and 23,000-share transactions at ~\$3.13–\$3.30), materially increasing her stake — another insider buy pattern reinforcing insider conviction. SEC Filing
- Neutral Sentiment: Press releases show closings of public offerings tied to the STEX ticker (announcements reporting $35M and $40.25M gross proceeds). If these refer to the same issuer, proceeds increase liquidity but also imply share issuance/dilution — impact depends on use of proceeds and whether this is the same corporate entity. Globe Newswire
- Negative Sentiment: Weiss Ratings initiated coverage with a "sell (d-)" rating, and MarketBeat shows an average analyst view of "Sell" — negative third‑party sentiment that can cap upside despite insider buying. Weiss Ratings
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
